▶OpenEvidence has achieved exceptionally high and rapid market penetration among US physicians, with multiple sources citing figures between 40% daily use and 50% overall adoption.Mar 2026

▶The platform is considered a trusted and essential tool for clinical decision-making, used by senior physicians at top-tier hospital systems and as a substitute for specialist consultations in under-resourced areas.Mar 2026

▶The company is recognized as a significant and influential player in the health tech AI sector, driving talent demand alongside other major companies like Abridge and Hippocratic AI.May 2026

▶OpenEvidence has a strong relationship with major medical journals, holding an exclusive license with the New England Journal of Medicine and ranking as its second-largest source of referral traffic after Google.Mar–Apr 2026

▶The precise user penetration rate is presented with slight variations; claims cite 'approximately 50% penetration,' '500,000 doctors... out of a total of one million,' and a more specific '40% of doctors... on a daily basis,' which represent different measurement criteria.Feb–Mar 2026

▶There is a contrasting view on the company's core identity. Sequoia is quoted describing it as 'a consumer internet company masquerading as a health care company,' emphasizing user growth, while another claim highlights its strategic decision to 'exclusively serve physicians and not patients,' which is a more traditional B2B enterprise focus.Mar 2026

▶The primary source of its competitive advantage is framed differently. One claim points to a 'proprietary data moat' from its exclusive journal licenses, while its rapid, viral growth and 'consumer internet' label suggest its user experience and product design may be the more critical factor.Apr 2026